TOXICOLOGICAL PROFILE FOR CHROMIUM - Davidborowski.com
TOXICOLOGICAL PROFILE FOR CHROMIUM - Davidborowski.com TOXICOLOGICAL PROFILE FOR CHROMIUM - Davidborowski.com
CHROMIUM 1482. HEALTH EFFECTS2.3.4.2 Oral ExposureGiven the low absorption of chromium compounds by the oral route, the major pathway of excretion afteroral exposure is through the feces.An acute, oral dose of radioactive chromium(III) as chromium chloride or chromium(VI) as sodiumchromate was administered to humans after which feces and urine were collected for 24 hours and 6 days,respectively, and analyzed for chromium. The amount of chromium in the 6-day fecal collection was99.6 and 89.4% of the dose for chromium(III) and chromium(VI) compounds, respectively. The amountof chromium in the 24-hour urine collection was 0.5 and 2.1% of the dose for chromium(III) andchromium(VI) compounds, respectively (Donaldson and Barreras 1966). In subjects drinking0.001–0.1 mg chromium(VI)/kg/day as potassium chromate in water for 3 days,
CHROMIUM 1492. HEALTH EFFECTSresulted in an extended time course of excretion. Approximately 76–82% of the 14-day total amount ofchromium in the urine was excreted within the first 4 days (mean peak concentration 209 µg chromium/gcreatinine; range 29–585 µg chromium/g creatinine). The average urinary excretion half-life for four ofthe volunteers was 39 hours at this dose. All subjects had returned to background concentrations(0.5–2.0 µg chromium/g creatinine) by 14 days post-dosing. About 87% of the total amount of chromiumin the urine measured over 8 days was excreted during the first 4 days for one volunteer ingesting0.03 mg chromium(VI)/kg (peak 97 µg chromium/g creatinine on day of ingestion). Urinary chromiumconcentrations had returned to an average of 2.5 µg chromium/g creatinine within 7 days post-dosing, thelast time point measured. Urinary excretion half-life in this volunteer was 37 hours. Similar time coursesof excretion were observed when volunteers took the same doses as daily doses over 3-day periods. Anearlier study by this group (Kerger et al. 1996a) examined urinary excretion half-lives following a bolusdose of 10 ppm (approximately 0.06 mg chromium/kg) chromium(III) chloride, potassium dichromatereduced with orange juice (presumably, the juice reduced the potassium dichromate to chromium(III)-organic complexes and chromium(III) ions), or potassium dichromate. The calculated urinary excretionhalf-lives for the three chromium solutions were 10.3, 15, and 39.3 hours, respectively. The potassiumdichromate half-life is consistent with the results from the Kerger et al. (1997) study.The urinary excretion kinetics of chromium have also been examined in eight adults that wereadministered chromium(III) at 400 µg/day as chromium(III) picolinate for 3 consecutive days (Gargas etal. 1994). The mean time to peak urinary concentration was 7.18±2.11 hours (range 2.9–13.0 hours), themean peak concentration being 7.92±4.24 µg chromium/g creatinine (range 3.58–19.13 µg/g creatinine).Excretion diminished rapidly after the peak but did not appear to return to background in most of thevolunteers before the next daily dose.Pharmacokinetic models were used to predict the retention and excretion of ingested chromium(III)picolinate (Stearns et al. 1995a). A single dose of 5.01 mg (assuming 2.8% or 140 µg of thechromium(III) picolinate is absorbed) resulted in 11 µg (7.9%) retained after 1 year. The model predictedthat about 1.4 µg would still be present in body tissues 10 years after dosing, and continuous dosing overa 1-year period would result in 6.2 mg of chromium(III) picolinate being retained, requiring about20 years to reduce the retained level to 0.046 mg. These projected retention estimates may be two- tofour-fold lower than results obtained from actual clinical findings. The authors caution that accumulativedaily intake of chromium(III) may result in tissue concentrations that could be genotoxic.
- Page 118 and 119: CHROMIUM 982. HEALTH EFFECTSchanges
- Page 120 and 121: CHROMIUM 1002. HEALTH EFFECTSsperma
- Page 122 and 123: CHROMIUM 1022. HEALTH EFFECTSchromi
- Page 124 and 125: CHROMIUM 1042. HEALTH EFFECTS2.2.2.
- Page 126 and 127: CHROMIUM 1062. HEALTH EFFECTSImpair
- Page 128 and 129: CHROMIUM 1082. HEALTH EFFECTSrates
- Page 130 and 131: TABLE 2-3. Levels of Significant Ex
- Page 132 and 133: HumanHumanHumanHumanHumanHumanHuman
- Page 134 and 135: CHRONIC EXPOSURESystemicHuman 7.5 y
- Page 136 and 137: CHROMIUM 1162. HEALTH EFFECTSNo stu
- Page 138 and 139: CHROMIUM 1182. HEALTH EFFECTSIrrita
- Page 140 and 141: CHROMIUM 1202. HEALTH EFFECTSindust
- Page 142 and 143: CHROMIUM 1222. HEALTH EFFECTSGuinea
- Page 144 and 145: CHROMIUM 1242. HEALTH EFFECTSmodel,
- Page 146 and 147: CHROMIUM 1262. HEALTH EFFECTSblood,
- Page 148 and 149: CHROMIUM 1282. HEALTH EFFECTSchromi
- Page 150 and 151: CHROMIUM 1302. HEALTH EFFECTSAlthou
- Page 152 and 153: CHROMIUM 1322. HEALTH EFFECTS2.3.2
- Page 154 and 155: CHROMIUM 1342. HEALTH EFFECTS2.3.2.
- Page 156 and 157: CHROMIUM 1362. HEALTH EFFECTSThe di
- Page 158 and 159: CHROMIUM 1382. HEALTH EFFECTS(2-5 m
- Page 160 and 161: CHROMIUM 1402. HEALTH EFFECTSIn rat
- Page 162 and 163: CHROMIUM 1422. HEALTH EFFECTSunstab
- Page 164 and 165: CHROMIUM 1442. HEALTH EFFECTSIn add
- Page 166 and 167: CHROMIUM 1462. HEALTH EFFECTSsignif
- Page 170 and 171: CHROMIUM 1502. HEALTH EFFECTSDaily
- Page 172 and 173: CHROMIUM 1522. HEALTH EFFECTS51 Chr
- Page 174 and 175: CHROMIUM 1542. HEALTH EFFECTS2.3.5
- Page 176 and 177: CHROMIUM 1562. HEALTH EFFECTSFigure
- Page 178 and 179: CHROMIUM 1582. HEALTH EFFECTSTable
- Page 180 and 181: CHROMIUM 1602. HEALTH EFFECTSFigure
- Page 182 and 183: CHROMIUM 1622. HEALTH EFFECTSInterr
- Page 184 and 185: CHROMIUM 1642. HEALTH EFFECTSthe bl
- Page 186 and 187: CHROMIUM 1662. HEALTH EFFECTSpreval
- Page 188 and 189: CHROMIUM 1682. HEALTH EFFECTS2.5 RE
- Page 190 and 191: CHROMIUM 1702. HEALTH EFFECTSSevera
- Page 192 and 193: CHROMIUM 1722. HEALTH EFFECTSanimal
- Page 194 and 195: CHROMIUM 1742. HEALTH EFFECTSOral M
- Page 196 and 197: CHROMIUM 1762. HEALTH EFFECTSfibros
- Page 198 and 199: CHROMIUM 1782. HEALTH EFFECTSNausea
- Page 200 and 201: CHROMIUM 1802. HEALTH EFFECTSthe pr
- Page 202 and 203: CHROMIUM 1822. HEALTH EFFECTSSevere
- Page 204 and 205: CHROMIUM 1842. HEALTH EFFECTSdevelo
- Page 206 and 207: CHROMIUM 1862. HEALTH EFFECTSthe ce
- Page 208 and 209: CHROMIUM 1882. HEALTH EFFECTSimprov
- Page 210 and 211: CHROMIUM 1902. HEALTH EFFECTSchroma
- Page 212 and 213: CHROMIUM 1922. HEALTH EFFECTSIn ano
- Page 214 and 215: Table 2-5. Genotoxicity of Chromium
- Page 216 and 217: Table 2-5. Genotoxicity of Chromium
<strong>CHROMIUM</strong> 1482. HEALTH EFFECTS2.3.4.2 Oral ExposureGiven the low absorption of chromium <strong>com</strong>pounds by the oral route, the major pathway of excretion afteroral exposure is through the feces.An acute, oral dose of radioactive chromium(III) as chromium chloride or chromium(VI) as sodiumchromate was administered to humans after which feces and urine were collected for 24 hours and 6 days,respectively, and analyzed for chromium. The amount of chromium in the 6-day fecal collection was99.6 and 89.4% of the dose for chromium(III) and chromium(VI) <strong>com</strong>pounds, respectively. The amountof chromium in the 24-hour urine collection was 0.5 and 2.1% of the dose for chromium(III) andchromium(VI) <strong>com</strong>pounds, respectively (Donaldson and Barreras 1966). In subjects drinking0.001–0.1 mg chromium(VI)/kg/day as potassium chromate in water for 3 days,